# A Phase II Study of Conversion Surgery After IP Paclitaxel With XELOX Chemotherapy in AGC With Peritoneal Dissemination

> **NCT04797923** · PHASE2 · UNKNOWN · sponsor: **Gangnam Severance Hospital** · enrollment: 43 (estimated)

## Conditions studied

- Advanced Gastric Cancer
- Peritoneal Carcinomatosis

## Interventions

- **DRUG:** 1. Treatment: IP chemotherapy + Systemic chemotherapy
- **PROCEDURE:** 2. Response evaluation after 4 cycles of IP + systemic chemotherapy

## Key facts

- **NCT ID:** NCT04797923
- **Lead sponsor:** Gangnam Severance Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-12-01
- **Primary completion:** 2021-06-30
- **Final completion:** 2021-12-30
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2021-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04797923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04797923, "A Phase II Study of Conversion Surgery After IP Paclitaxel With XELOX Chemotherapy in AGC With Peritoneal Dissemination". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04797923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*